Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries

Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries

Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such...

Full description

Saved in:
Bibliographic Details
Main Authors: Mathias Flume, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, Maarten J. Postma, Nicolas Touchot
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Budget impact
affordability
cost effectiveness
market access
funding
expensive therapies
health technology assessment
price negotiation
Online Access:http://dx.doi.org/10.1080/20016689.2018.1478539
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1080/20016689.2018.1478539

Similar Items